$ATXI
AVENUE THERAPEUTICS, INC.

2018 Q3 Form 10-Q Financial Statement

#000114420418044262 Filed on August 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $820.0K $930.0K $1.300M
YoY Change -3.53% -28.46% 490.91%
% of Gross Profit
Research & Development $1.788M $3.754M $447.0K
YoY Change -10.6% 739.82% 6.18%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.788M $3.754M $1.744M
YoY Change -37.22% 115.25% 173.35%
Operating Profit -$2.608M -$4.681M -$1.744M
YoY Change -8.43% 168.41% 173.35%
Interest Expense $0.00 $0.00 $93.00K
YoY Change -100.0% -100.0% 6.9%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 -$662.0K
YoY Change -100.0% -100.0% 397.74%
Pretax Income -$2.600M -$4.660M -$2.410M
YoY Change -11.86% 93.36% 212.99%
Income Tax
% Of Pretax Income
Net Earnings -$2.595M -$4.657M -$2.406M
YoY Change -11.97% 93.56% 212.06%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$252.4K -$454.6K -$289.0K
COMMON SHARES
Basic Shares Outstanding 10.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.800M $8.940M $34.68M
YoY Change -81.57% -74.22%
Cash & Equivalents $4.804M $8.940M $34.68M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $460.0K $500.0K $20.00K
YoY Change 253.85% 2400.0%
Inventory
Prepaid Expenses $22.00K
Receivables
Other Receivables
Total Short-Term Assets $5.260M $9.440M $34.71M
YoY Change -79.91% -72.8%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.000K -$4.000K -$5.000K
YoY Change -175.0% -20.0%
TOTAL ASSETS
Total Short-Term Assets $5.260M $9.440M $34.71M
Total Long-Term Assets $3.000K -$4.000K -$5.000K
Total Assets $5.263M $9.436M $34.71M
YoY Change -79.89% -72.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $770.0K $3.194M $830.0K
YoY Change -59.69% 284.82%
Accrued Expenses $1.700M $1.230M $340.0K
YoY Change 2025.0% 261.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.990M
YoY Change
Total Short-Term Liabilities $2.469M $4.419M $7.155M
YoY Change 24.07% -38.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $390.0K
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $390.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.469M $4.419M $7.155M
Total Long-Term Liabilities $0.00 $0.00 $390.0K
Total Liabilities $2.469M $4.419M $7.549M
YoY Change 24.07% -41.46%
SHAREHOLDERS EQUITY
Retained Earnings -$38.29M -$35.70M -$11.47M
YoY Change 165.57% 211.2%
Common Stock $41.08M $40.71M $38.63M
YoY Change 6.42% 5.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.794M $5.017M $27.16M
YoY Change
Total Liabilities & Shareholders Equity $5.263M $9.436M $34.71M
YoY Change -79.89% -72.81%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$2.595M -$4.657M -$2.406M
YoY Change -11.97% 93.56% 212.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.140M -$6.020M -$630.0K
YoY Change 121.39% 855.56% 162.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 35.30M
YoY Change -100.0% -100.0% 14020.0%
NET CHANGE
Cash From Operating Activities -4.140M -6.020M -630.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000 35.30M
Net Change In Cash -4.140M -6.020M 34.67M
YoY Change -77.77% -117.36% 346600.0%
FREE CASH FLOW
Cash From Operating Activities -$4.140M -$6.020M -$630.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Use Of Estimates
UseOfEstimates
<div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.25in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3194000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1545000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
134000 USD
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
215000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3754000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
447000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13193000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
580000 USD
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Net Income Loss
NetIncomeLoss
-15034000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3067000 USD
dei Document Type
DocumentType
10-Q
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1913000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1668000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
927000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1297000 USD
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
906000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
977000 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.29
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4234000 USD
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2737000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4681000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1744000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-15106000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2248000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8940000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11782000 USD
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation
ShareBasedCompensation
671000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
24000 USD
atxi Fair Value Adjustments Of Convertible Notes Payable
FairValueAdjustmentsOfConvertibleNotesPayable
0 USD
atxi Fair Value Adjustments Of Convertible Notes Payable
FairValueAdjustmentsOfConvertibleNotesPayable
99000 USD
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
CY2016Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
250000 shares
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
10000000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
72000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
24000 USD
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.29
CY2018Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2017Q2 us-gaap Interest Expense
InterestExpense
93000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
188000 USD
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
943332 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
449999 shares
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
496000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
388000 USD
CY2016Q3 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.025 pure
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
451000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
68000 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2017 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1100000 USD
CY2016 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
49000 USD
CY2018Q2 us-gaap Assets
Assets
9436000 USD
CY2017Q4 us-gaap Assets
Assets
22170000 USD
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
81000 USD
CY2018Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0 USD
CY2017Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
20000 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y7M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M17D
CY2018Q2 atxi Fair Value Adjustments Of Convertible Notes Payable
FairValueAdjustmentsOfConvertibleNotesPayable
0 USD
CY2017Q2 atxi Fair Value Adjustments Of Convertible Notes Payable
FairValueAdjustmentsOfConvertibleNotesPayable
95000 USD
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10554170 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10265083 shares
dei Entity Registrant Name
EntityRegistrantName
AVENUE THERAPEUTICS, INC.
atxi Issuance Of Common Shares For Founders Agreement
IssuanceOfCommonSharesForFoundersAgreement
0 USD
atxi Issuance Of Common Shares For Founders Agreement
IssuanceOfCommonSharesForFoundersAgreement
948000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
19380000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
108000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
22000 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001644963
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10265083 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10554170 shares
CY2018Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
454000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-4657000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-2406000 USD
CY2018Q2 atxi Common Stock Shares Issuable
CommonStockSharesIssuable
0 shares
CY2017Q4 atxi Common Stock Shares Issuable
CommonStockSharesIssuable
273837 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1497000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
320000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
132000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
451000 USD
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
185000 USD
CY2017Q4 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
53000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.48
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10251950 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3459942 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10176062 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3242602 shares
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4419000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2790000 USD
dei Trading Symbol
TradingSymbol
ATXI
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-1000 USD
atxi Share Issued During Period Valueon Exercise Of Warrants
ShareIssuedDuringPeriodValueonExerciseOfWarrants
0 USD
atxi Accrued Interest Related Party
AccruedInterestRelatedParty
0 USD
atxi Accrued Interest Related Party
AccruedInterestRelatedParty
74000 USD
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10554420 shares
CY2018Q2 us-gaap Liabilities
Liabilities
4419000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
2790000 USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12842000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-655000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
671000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
10000000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
5017000 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2017Q2 atxi Service Agreement Expenses
ServiceAgreementExpenses
100000 USD
atxi Service Agreement Expenses
ServiceAgreementExpenses
300000 USD
CY2018Q2 atxi Service Agreement Expenses
ServiceAgreementExpenses
100000 USD
atxi Service Agreement Expenses
ServiceAgreementExpenses
300000 USD
CY2018Q2 atxi Common Stock Value Issuable
CommonStockValueIssuable
0 USD
CY2017Q4 atxi Common Stock Value Issuable
CommonStockValueIssuable
1103000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37950000 USD
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
40711000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38937000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35695000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20661000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3447000 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
638000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9436000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22170000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35141000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-2842000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
34486000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
125000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
197000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34683000 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1000000 USD
atxi Warrants Issued
WarrantsIssued
0 USD
atxi Warrants Issued
WarrantsIssued
750000 USD
atxi Extinguishment Of Fortress Compensation Accrual
ExtinguishmentOfFortressCompensationAccrual
0 USD
atxi Extinguishment Of Fortress Compensation Accrual
ExtinguishmentOfFortressCompensationAccrual
632000 USD
atxi Interest On Fortress Note On Modification
InterestOnFortressNoteOnModification
0 USD
atxi Interest On Fortress Note On Modification
InterestOnFortressNoteOnModification
300000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
200000 USD
atxi Change Fair Value Of Convertible Note Warrents
ChangeFairValueOfConvertibleNoteWarrents
0 USD
atxi Change Fair Value Of Convertible Note Warrents
ChangeFairValueOfConvertibleNoteWarrents
15000 USD

Files In Submission

Name View Source Status
0001144204-18-044262-index-headers.html Edgar Link pending
0001144204-18-044262-index.html Edgar Link pending
0001144204-18-044262.txt Edgar Link pending
0001144204-18-044262-xbrl.zip Edgar Link pending
atxi-20180630.xml Edgar Link completed
atxi-20180630.xsd Edgar Link pending
atxi-20180630_cal.xml Edgar Link unprocessable
atxi-20180630_def.xml Edgar Link unprocessable
atxi-20180630_lab.xml Edgar Link unprocessable
atxi-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv499145_10q.htm Edgar Link pending
tv499145_ex3-1.htm Edgar Link pending
tv499145_ex31-1.htm Edgar Link pending
tv499145_ex31-2.htm Edgar Link pending
tv499145_ex32-1.htm Edgar Link pending
tv499145_ex32-2.htm Edgar Link pending